Market Spotlight: Duchenne Muscular Dystrophy (DMD)
|出版日期||內容資訊||英文 56 Pages
|關注市場分析:裘馨氏肌肉萎縮症 (DMD) Market Spotlight: Duchenne Muscular Dystrophy (DMD)|
|出版日期: 2020年02月19日||內容資訊: 英文 56 Pages||
本報告提供裘馨氏肌肉萎縮症 (DMD)的治療藥市場相關分析，疾病概要和患者數的變化、預測，目前的主要的治療方法，法規環境和近幾年主要的事件，現在開發中臨床實驗的進展與上市計劃，主要的治療藥的市場趨勢預測 (今後10年份)，資本交易的動向等調查。
This Market Spotlight report covers the Duchenne Muscular Dystrophy market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, probability of success, recent events and analyst opinion, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2017, there were 182,100 prevalent cases of Duchenne muscular dystrophy (DMD) in males worldwide, and forecasts that number to increase to 199,100 prevalent cases by 2026.
Approved drugs in the DMD space target glucocorticoid receptor, dystrophin gene, and RNA translation. These drugs are administered via the oral and intravenous routes.
The largest proportion of industry-sponsored drugs in active clinical development for DMD are in Phase II, with only drugs in the NDA/BLA phase.
Therapies in development for DMD focus on a wide variety of targets. The majority of pipeline drugs are administered via the intravenous or oral routes, with the remainder being intramuscular, intraarterial, and subcutaneous formulations.
High-impact upcoming events for drugs in the DMD space comprise topline Phase I/II, Phase II, Phase Iib, and Phase III trial results, an estimated PDUFA date for an NDA, and an expected option exercise decision.
The overall likelihood of approval of a Phase I DMD asset is 21.8%, and the average probability a drug advances from Phase III is 62.5%. Drugs, on average, take 8.6 years from Phase I to approval, compared to 8.9 years in the overall metabolic space.
There have been 21 licensing and asset acquisition deals involving DMD drugs during 2015-20, seven of which occurred in 2017. The largest deal during the period was the $3,520m licensing agreement between Vertex and CRISPR Therapeutics signed in 2017, as part of which the two companies will discover and develop gene editing therapies for the treatment of DMD and myotonic dystrophy type 1 (DM1).
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for DMD have been in the early and midphases of development, with 71% of trials in Phase I-II, and only 29% in Phase III-IV.
The US has a substantial lead in the number of DMD clinical trials globally. The UK leads the major European markets, while Israel has the top spot in Asia.
Sarepta Therapeutics has the highest number of ongoing clinical trials for DMD, with 10 trials.
Sarepta Therapeutics leads industry sponsors with the highest number of clinical trials for DMD, followed by PTC Therapeutics.